What is the prognosis for patients with scleroderma?

Condition analysis:
A patient's prognosis is optimized with close monitoring of overall health status and treatment of complications, especially elevated blood pressure. Recent data indicates that the critical period of organ risk is generally within the first three years of skin involvement. This means that patients can be reassured that their risk of organ-threatening complications is significantly less after three years of having skin symptoms.

Much more research is needed in all areas of scleroderma disease, from cause to treatment. Today scleroderma continues to challenge medical scientists. Researchers are evaluating the effectiveness of thalidomide (Thalomid) for the treatment of scleroderma. More sensitive tests to detect early lung disease of scleroderma are also being evaluated. Psoralen and ultraviolet light therapy (PUVA) is being studied as a possible treatment for limited scleroderma.

Many researchers are investigating the roles of various cell messengers, called cytokines, in causing scleroderma. Researchers are also currently studying a hormone of pregnancy, called relaxin, for the treatment of scleroderma. Preliminary results suggest that it may improve scleroderma. Relaxin normally loosens the ligaments of the pelvis and ripens the womb for childbirth. How it might work in scleroderma is unclear.

It is clear that our understanding of the effects of the immune system in scleroderma is greatly improving. A vast number of clinical research trials are underway that are evaluating potential treatments for various aspects of the disease to improve the prognosis for the patient.

Instructions:
Avoid Heavy Foods: Scleroderma causes havoc in the digestive tract. The best way to keep the symptoms under control is by watching what you eat. Avoid late-night dinners, heavy foods that create gas or acidity. Prop extra pillows under your head when you sleep to avoid acid reflux. You can also consider using antacids.